U.S. FDA Grants Fast Track Designation to Novavax' RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization
20 nov. 2014 08h30 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP
17 nov. 2014 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax to Present at the Jefferies Global Healthcare Conference
13 nov. 2014 09h23 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects
10 nov. 2014 08h30 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
06 nov. 2014 17h19 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax Reports Third Quarter 2014 Financial Results
05 nov. 2014 16h13 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax to Host Conference Call to Discuss Third Quarter 2014 Financial Results on November 5, 2014
30 oct. 2014 08h30 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM)
29 oct. 2014 17h17 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia
27 oct. 2014 07h30 HE
|
Novavax, Inc.
First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic Sequence
Robust immune responses demonstrated in preclinical studies; exceptional responses when used with Novavax'...
Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26
26 oct. 2014 10h00 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Oct. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...